

Dengies 🐔 lakomoyeane. 🖾 Sanamaesis des									
856MUE 2410/2019 (In Program) #		* Surcharació dela *							*
System Code: MMMANT Diagnosis: exclosed Protocols C/V Edit Horapy details		Somatometri	: data						
Status in Progress Tumor: Therapy start date: 74/03/2014 December		Weght Address	0.00/0109 T 13,00/01						
Deopy Schedule	1	Meght Additor	503rg 101 190,00m		100eg 96.00eg	9520kg			
Cycle 1 Duration 21 days 24 February 2019 16 March 2019	1								
pg 24 Televary 2018 - Gay 19	1	Libratily name X							
Vinciatine 1-Adrophn' Intervence	Crickrod - Repared	Laboratory ex	ams						
Cyclophosphamide 1,00030mg/m ² intravencus	Ordered - Repared	11. T	0 exp 1 feet 10 g 10 e 10 700						
Davardakin 40.00 ng/m² inter-anous	Octared - Repared		Lab lett		wane 7 wittane	7 1402079 7	Terrorater T	18/02/079 7	
			Centerra D	Address				100.00mg/1	
Cycle 2 - Doutier 21 days 17 March 2019 - 96 April 2019	1			Address Address			98.925		
Cycle 3 - Ocontine 21 Jays - 87 April 2019 - 27 April 2019			ACTING Biodes (Creed)	Address	100	2010umol1			
	1	Cancer Markets	CA 125	Address					
Syde 4 - Sustan 21 days 28 April 2019 - 16 May 2019	1	Motabolic Disordors Cancer Varkers		Add new Add new		2000mat/m			
Cycle 5 - Duation 21 days 99 May 2019 - 00 June 2019	1		CTA CTA	Address			500,001		
Cycle 8 - Dustion 21 days 10 June 2019 - 20 June 2019	1		hatsaida	Addres					
			Ritchin (online) Heredourk	Address 1 Address	DOJDme45				
			PSA	Add nex					
			10H 6H09	Add res					
			\$ HCB	Addition		-			
		Penantoji:	Aboris	Address					
			OT Protorgation Chatter	Add nex		_			
			this Bool Cells W9C						
		Metabolic Disorders	Megnesum	Address					
			209 Posteinuria	Add new Add new					
				Addres			-		
					-	1	1		
				_		_			-



Management of Chemotherapy from Prescription to Production





Innovative approach to prescribing

erro K Pat I De	w X Plannary X		Protocal Properties				17.3						
armacy			Nativ	e CAR									
Clerk tor new	athron .		Description	Costenent tenerate 1 colong	w' at		10						
Contactor real	+ Puteral Nervarment			Observation 45.00 mp/m ⁴ , o	1		8						
a sheet water a	Postovak	Protocols	Verifics	Visition 140 mpm ² .01									
te T Mete	Tumon	0 8 mmt						name T e	hamaceutical	in a	311		
DATE WITH	Terrar sategoria	Day a place having and man 1 Key lange	numor categoriet	• - Sead Celliarg Carper 3	and select configurate				Accelle Substi	-	12		
WHELD Caple	Meticines Database		Contraction of the local division of the loc	Not listed? Add rate -			100		potable Soluti	ça.	E		
NARU Ciscle	 Diseases III Lab Tests 	5 m	resource of sports	· · · · · · · · · · · ·	emone namps				jectable Soluti	cn.	R		
PITER HARD	# Carligeration	Nab Ruckand 200	Broat C Eyrle duration	1 21 5 ceys twintin	duration system?		- 11		vertable Soluti	68	2		
ONE Daves	Application Desenators	FEC-100	8/cast.C				- 20	000000000	geratie Soluti		P.		
ILASS Cysler	Detabase	Ceplatin 80+ Inspasse 108		rapy regimen			12/2	2019 23 50 35 8	weeker for Solut	tion for bijection	12		
date Vinal	lius	Instean	Saulte 10 @ ha	ert.			12.0	2019 22 30 40 1	peciable Subesi	en.	12		
ena Calva		Ceptano «Viscorib ne	Nan Sey	T Steen station made T	Denage 7		32/2	019141707	dectable Solution	én.	P		
Mapp View		Hoslamide - Pacitanel	Utarine Versist et		Libroini / 1		32/2	2019 13 46 11	jectable Soluti	on.	2		
MARC Direct		5 RJ Galain	Buying Containing		45.00mg/m* / 1		14.1	UT9134251	vectable Soluti	ca.	P		
con cyrin		Capitalin 75-80+Veranabiline 25-36	Not bea		10 Protocol Medicine Prop		-				. 12	- C X	1
ALDE Daries		Capitatin 50+ Etopoiside 50	Npt Sec	the manual second								- 0 x	
		IC+INANA	Unext C		Medicin	Descrubice						A (1)	
		Engline-Davenibies	Orestall		-00200	Not interf Add to							
		Liposcenal Descrubice 10	Breast G			45-00mp/m ⁴ 04	t as range						
		Roulamide - Capital-	Userine E		Administration roub							9)	
		Tapetucan 13	Shut Ce			Not Know? Add no	e						
		G4V	Small Corvung Lancer	**	Note	•							
		CME po	Breatt Cancer		-								
		Capiton 71 - Report auto 500	Non-Small Cell Long Cancer	4	_								
		Ceptanin 100-dhopoelde 190	Non Small Cell Long Cencer	4	Administratio	on Schedule							
		Cisplatin - Vinclutan	Small Call Long Cancer	4	Bulk actions	idect bulk action -	* Ga						
		Cisplatin (Doucland)	Non Small Cell Long Cancer	4	crart:								
		Coturinab - Capitalin 75-100	Head and Neck Cancers	4	Week1: ZDay	1 04/2	[[lity]	E0v4	0.91	_0.ey#	3/m/2 3/m/4		
		Osplatin 25+Blopos de 106	Shall Cell Lung Cancer	4-1	Week2: Day Week3: Day	5 Cey9	Eley10 Eley17	Day 11	Deg 12	Doin 13 10//20	29y14 10er21		1
		Ceptatro-Centrals are Centario 100e Vinovelhine 10	Non Small Cel Lung Lancer	4	CYCLE2								
			Non-Small Cell Long Concer	4	Week 1: 200 Week 2: 00y	1 Eury2 6 Eury0	Euy3 Euy10	EDuy-4 Day 11	Day 5 Day 12	04/6 04/13	2497 20ay 14		1
		1			Week Is Day	15 Dey16	Elay 17	Day 18	Tilley 19	10.978	They?t		
		11111			CICULI								1
					Weak1: ViDus Weak2: Day	1 Evy2 8 Evy2	Eury 2 Eury 10	Day 1	Day 12	0a/6 0a/13	10ay7		1
					Week 1: 30y	11 🗍 Day16	E Day 17	EDw's	Doy 14	Doga	(Day)		1
												~	1
										Cancel	See	Save and close	1
													1

Unique tools

Therapeutic Protocols

- Enhances Safety
- Serves as a framework for development of facility's policies and procedures
- Contains more than 600 current, evidence-based treatment Protocols
- Custom Protocol Creation as requested by prescriber

Therapy Plan and Organizer

- Efficiently tracks prescriptions to be compounded based on patient cycle of therapy
- Structured model ensuring uniform approach for all electronically ordered prescriptions
- Pharmacist validation system
- Compounding planning system
- Complete traceability and audit trail of all user actions

Complete tracker of patient therapy, laboratory data, biochemical markers

Day Week	Month	Show Details Today					
Monday		Tuesday		Wednesday		Thursday	
	Mar 01		02		03		04
		BAPB ΣΒΟΛ - CARBOplatin - PACLitaxel	^	AP FIAN - Gemcitabine - Bevacizumab - CARBOplatin	^	5 010169 - Trastuzumab - PERTuzumab	^
		EYA XAA - PACLitase - PACLitase - CAR8Oplatin ap mearu 09 FED 400/eA - PERTuzumab - PERTuzumab - riastuzumab mickey mouse 123 - vincRistine - OydOn/bubicn - OydOn/bubicn		AΓΠΙΣΤ - Trastuzumab emtansine		KYP KATΣ - CARBOplatin - Bevacizumab - PACLitaxel	
	08			FEO SKIAA	10	- PACLITAXEI	11
Παπανδρεου Πανος 123 - DOXOrubicin - vinCRIStine - Cyclophosphamide				Aσθενής 1 - PACLitaxel ΓΕΩ ΣΚΙΑΔ - PACLitaxel	Î	panos papandreou12345 - Cyclophosphamide - DOXOrubicin - vinCRIStine	
MAPO ΣΩΤ - Capecitabine				MAPO ΣΩT - Capecitabine	~	ppap ppap - Cyclophosphamide - vinCRIStine	
	15		16		17		18
		AP ΦΡΑΓΚ - PACLitaxel				panostest1 papandreou - vinCRIStine - Cyclophosphamide - DOXOrubicin	

Standardizing the route to individualized Therapy Incorporated prescriber Protocols





Quality & Safety

Dosage adjustment / postponment rules

Protocol Rules

Platelets, PLT / Between Or Equal: 75.00x10^9/L - 99.99x10^9/L

Adjustment of dosage to 50% is recommended.

Safety Alerts / Dose Adjustments

Recommendations to prescriber on dose changes based on:

- Creatinine Clearance
- Liver Function Tests
- ANC/Platelets
- Narrow Therapeutic Index
- And more...

Ability to postpone day of therapy or treatment cycle

Preparation

- Accurate step by step instructions to ensure safe and error free reconstitution, dilution and preparation
- Recommendation of cost-effective vial sizes for production
- Mitigation of calculation errors
- Maximization of compounding time efficiency
- Left Over Medication log and use mechanisms (partially used vials) which reduce hospital medication waste

PREPARATION INSTRUCTIONS

BHWB26BN

Last Name	2	SSN
First Name	test	For administration 20/05/2021 at
Therapy	1INEL7MJ : Cycle 3 / Day 1	Attendant doctor
Medicine	Cyclophosphamide	Prescribing doctor
Admin. dosing	1,886.28mg	Administration IV Infusion / 30.00min

STEP 1: MEDICINE SELECTION

1. Get 2 Vial from 2 CYCLOPHOSPHAMIDE 1,000 mg powder for solution (Vial 1 & 2).

WARNING: Selected products exceed prescribed dosage by 113.72mg

STEP 2: RECONSTITUTION

1. Reconstitute using 50.00ml Sodium Chloride 0.9% for the vial 1 (CYCLOPHOSPHAMIDE 1,000 mg powder for solution).

2. Reconstitute using 50.00ml Sodium Chloride 0.9% for the vial 2 (CYCLOPHOSPHAMIDE 1,000 mg powder for solution).

The total volume after reconstitution will be 100.00ml and the concentration will be 20.00mg/ml

STEP 3: DILUTION

From the reconstituted total solution of 100.00mI, you will keep 94.31mI which you will further dilute with 250.00mI Sodium Chloride 0.9%.

The dilution will take place in a new container with minimum capacity 344.31ml

- 1. Transfuse 250.00ml Sodium Chloride 0.9% to the new container
- 2. From the reconstituted Vial 1 of 50.00ml transfuse 50.00ml to the new container
- 3. From the reconstituted Vial 2 of 50.00ml transfuse 44.31ml to the new container.

The final volume of the solution must be 344.31ml.

STEP 4: ADMINISTRATION

- Administration route: IV Infusion Administration time/rate: 30.00min
- Expiration: 24.00h

LEFT-OVER

At the reconstituted Vial 2 there is a left-over of 5.69ml /113.72mg

Expiration: 24.00h

Safety Support Tool

Compounding Guidelines Based on Available Products





Chemotherapy Order

System Code: 3HCF08CS Diagnosis: dd Status: In Progress Turnor:	dd Protocol: Paclitaxel + Cisplatin + Doxorubicin Therapy start date: 25/02/2019	Edit therapy details Delse therapy	
Therapy Schedule			
Cycle 1 - Duration: 21 days 25 February 2	2019 - 17 March 2019		
🛱 25 February 2019 (Day 1)			
Doxorubicin 45.00mg/m ² Intravenous			Ordered - Prepare
Cisplatin 50.00mg/m ² Intravencus			Ordered - Pendin
26 February 2019 (Day 2)			
Paclitatel 150.00mg/m ² Intravenous			
Cycle 2 - Duration: 21 days 18 March 201	19 - 07 April 2019		
18 March 2019 (Day 1)			
Doxorubicin 45.00mg/m² Intravenous			
Gisplatin 50.00mg/m² Intravancus			
19 March 2019 (Day 2)			
Paclitaxel 150.00mg/m ² Intravenous			
Cycle 3 - Duration: 21 days 08 April 2019	- 28 April 2019		
Cycle 4 - Duration: 21 days 29 April 2019			
Cycle 5 - Duration: 21 days 20 May 2019	-		
Cycle 6 - Duration: 21 days 10 June 2019	- 30 June 2019		

Setting

Protocol Management
 Medicines Database
 Diseases & Lab Tests

Configuration Users

Intuitive Order Template

Protocol Based Template

- Saves time & decreases the risk of errors
- User friendly interface
- Allows modifications
- Documented Therapeutic Plan and Innervations

Inventory Database

Contains complete list of medications, both brand and generic, used per Hospital formulary

Allows production in accordance with availability

🖒 🕀 Insert						
Drag a column header and drop it he	ere to group by that column					
Name T	Active substance	Company T	Form			
Cisplatin 10 mg/ 10 ml	Cisplatin	Hospira	Injectable Solution	1	Û	
Cisplatin 1 mg/ 1 ml	Cisplatin	Accord Healthcare Ltd	Injectable Solution	1	Û	
Cisplatin 50 mg/ 50 ml	Cisplatin	Hospira	Injectable Solution	1	Û	
Carboplatin 50 mg/ 5 ml	Carboplatin	Accord Healthcare Ltd	Injectable Solution	1	Û	
Cisplatin 100 mg/ 100 ml	Cisplatin	Hospira	Injectable Solution	1	Û	
Paclitaxel 150 mg/ 25ml	Paclitaxel	Hospira	Injectable Solution	1	Û	
Doxorubicin 200 mg/ 100 ml	Doxorubicin	Seacross Pharmaceuticals Ltd.	Injectable Solution	1	Û	
Paclitaxel 300 mg/ 50 ml	Paclitaxel	Accord Healthcare Ltd	Injectable Solution	1	Û	
Pemetrexed 500 mg	Pemetrexed	medac GmbH	Powder for Solution for Injection	1	Û	
Cyclophosphamide 1,000 mg	Cyclophosphamide	Baxter	Powder for Solution for Injection	1	Û	
Cisplatin 10 mg/ 10 ml	Cisplatin	Accord Healthcare Ltd	Injectable Solution	1	Û	
Paclitaxel 300 mg/ 50 ml	Paclitaxel	Accord-UK Ltd.	Injectable Solution	1	Û	
Doxorubicin 10 mg/ 5 ml	Doxorubicin	Accord Healthcare Ltd	Injectable Solution	1	Û	
Cisplatin 10 mg/ 10 ml	Cisplatin	Sandoz	Injectable Solution	1	Û	
Vincristine 1 ma/ 1 ml	Vincristine	Pfizer	Iniectable Solution	1	Ĥ	

Smart


- Multilingual Interface
- Automatic Calculations of total volume of medications and diluents
- Compounding / Dilution Instructions
- Infusion Rate
- Customized alerts
- Interchange between Metric Units
- Multi User (Prescriber/Pharmacist Interface/Compounding/Nursing)
- Includes Nursing Module for on-time medication dispatch and administration
- HL7 Compatibility Module

Decision Support Tool Enhances Compliance





Full Integration with ACD



Multiple Label functionality

Fully - Customizable Label

- Includes all elements for proper identifications and administration as per guidelines
- Prescription Label, Bag Label, Left-Over Label
- QR code that allows for remote production

Direct Communication with ACD for automated IV production

Flawless Production Clinically Proven and Tested





Service

Customized installation

Full customization of databases and features of the system based on facility's needs. Flexible solution, adaptable to institutions workflows.

Support

Dedicated professional team of Doctors, Pharmacists, Nursing Staff and Software Engineers, always there to support each individual need.

Continuous Software Development

(At least) two software updates annually, including updates to evidence-based therapeutic protocols, custom medication alerts, other customer requests.

Training

Our team will take control of all level training – from Nursing and Medical staff, to IV room production, with a single scope of enhancing quality and compliance to the institution's policies on Total Quality Management GMP.

End-User and International Experience


A team with extensive professional and academic experience in major international Universities and Institutions, with the capacity to comprehend end-user needs and desires.

Personalized Service Uncompromised Expectations

©CibusMed 2019







CIBUSMED

www.cibusmed.com info@cibusmed.com